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Summary A cDNA library constructed from mRNA from a human breast carcinoma metastasis was
screened with a polyclonal antibody to deglycosylated human milk fat globule membrane, resulting in the
isolation of eight clones from a total of 105 plaques. One of these (J16) was identified as lactoferrin. It was
highly expressed (as a 2.5 Kb mRNA) in lactating breast and in both normal resting tissue taken from
adjacent to carcinoma or from reduction mammoplasties. Immunoreactive lactoferrin was localised to ductal
cells and their secretions in both normal and mildly hyperplastic ducts. In a normal tissue screen J16 was
highly expressed in stomach, poorly in skin and lymphocytes and absent from other organs examined. It was
variably expressed in 33/59 invasive primary breast tumours; lactoferrin protein in these was heterogeneously
distributed in epithelial tumour foci. Presence of J16 was inversely related to expression of oestrogen receptor
protein (P = 0.0001). There was no significant relationship to other clinical parameters. We also found
immunoreactivity in 20/41 (49%) cases of ductal carcinoma in situ. Expression was not observed in any breast
or gastric cell line examined. Thus lactoferrin appears to be down regulated in some forms of cancer. The
presence of lactoferrin could be a contraindication for effective endocrine therapy.
Changes in cell surface or associated antigens are implicated
both in normal cellular processes such as differentiation and
immunodetermination, and in the phenotypic expression of
neoplasia (Reisfeld & Cheresh 1987; Sulitizeanu, 1985).
Identification of susceptible epitopes would further our
understanding of malignant progression and could provide
potential targets with clinical applications. The human milk
fat globule membrane (HMFGM), derived from the luminal
epithelial cell surface shed into breast milk is well established
as a source of breast glycoproteins.
By extending previous approaches, we have used poly-
clonal antisera, raised against carbohydrate depleted
HMFGM (Gendler et al., 1987) to immunoscreen a cDNA
phage expression library (Young & Davis, 1983) constructed
from human breast carcinoma metastasis mRNA. One of the
immunoreactive clones isolated (Campbell et al., 1990) was
identified as encoding part of the recently sequenced lactofer-
rin gene (Rado et al., 1987; Powell & Ogden, 1990). A major
component of human milk, lactoferrin has been shown to be
regulated in mouse uterus and mammary gland by oestradiol
and prolactin respectively (Teng et al., 1989). Although
reported to be widely distributed in murine tissues, its expres-
sion appears to be more limited in human tissues,
predominantly to the glandular organs (Mason & Taylor,
1978). In human breast carcinomas, previous immuno-
cytochemical studies have yielded conflicting results. Mason
and Taylor (1978) reported one positive case out of 12
carcinomas, Wurster et al. (1980) found 42% of their cancers
to be positive, Charpin et al. (1985) 5/67, Rossiello et al.
(1984) failed to find any positives in 40 cases and Wrba et al.
(1986) in their series of 91 reported 60.4% positivity.
To extend these studies and attempt to resolve some of the
differences we used our isolated cDNA clone to investigate
lactoferrin expression at the RNA level in a variety of breast
carcinomas and cell lines and compared this with several
normal human tissues. We also used an antibody to study
lactoferrin protein localisation, in particular, in a series of in
situ ductal carcinomas (DCIS).
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Materials and methods
Materials
All materials were obtained from Sigma Chemical Co.
(Poole, Dorset, United Kingdom), unless otherwise stated.
Cell culture
The human breast cell lines (Engel & Young, 1978) were
maintained in Dulbecco's minimum essential medium con-
taining phenol red, supplemented with 10% foetal calf serum
and antibiotics. The HbL 100 and HBrSVI.6.I lines were
from Dr M. O'Hare, the 184AI and 184B5 from Dr M.
Stampfer and the others, MCF7, T47D, ZR75-1 and MDA-
231 as previously indicated (Skilton et al., 1989). The gastric
lines, MKN-1, MKN-28, MKN-45, KATO 111 and SCH
were provided by Dr T. Motoyama and these were main-
tained in RPMI-1640 containing glutamine and the supple-
ments as above.
Tissue samples
Breast tissues were collected at the time of surgery from
patients attending the Breast Clinics principally at St
George's and the Royal Marsden Hospitals, London, snap
frozen and stored in liquid nitrogen. In all cases of breast
tumour, histological confirmation of diagnosis was obtained.
Breast reduction mammoplasty tissue was also used as a
source of non malignant breast and in general was processed
into organoids (Skilton et al., 1989). Non-breast normal tis-
sues were either collected fresh from operating theatres at St
George's or in some cases were from post-mortem material.
Archival paraffin embedded materal was from the pathology
departments of the above hospitals, and the blocks contain-
ing DCIS were kindly made available by Mr J.C. Gazet. This
latter series of patients were subdivided using established
histological criteria into groups exhibiting cribriform, com-
edo, solid or micropapillary DCIS (Page et al., 1987). In
some cases, more than one type was recorded on the same
section. Only those with no evidence of invasive carcinoma
were included in this part of the study.
Preparation and deglycosylation ofhuman milkfat globule
membrane
Milk from mothers 1-7 days post partum was processed as
described (Gore et al., 1984) for deglycosylation using
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trimethanesulphonic acid. The final HMFGM pellet was
diluted at least three times with 10 mM Tris-HCI pH 7.5
containing 5 mM Phenylmethylsulfonyl fluoride, and centri-
fuged at 140,000g for 1.5 h at 4°C. The membrane fractions
were stored in aliquots at -40°C.
Protein content was assayed with Bio-Rad protein dye
reagent (Bradford, 1976). Carbohydrate content was assayed
as follows: to 100jlI sample 300 1L water was added, 10Il
80% phenol (w/v in water, plus a few drops of IN NaOH)
plus 1 ml concentrated H2SO4. After 15 min at room
temperature the absorbance was measured at 490 nm. Suc-
rose was used for calibration.
Immunisation ofrabbits
Rabbits were immunised four times with approximately
100 jig ofcarbohydrate-stripped (CHO-)HMFGM emulsified
in Freund's complete adjuvant, with 4-6 weeks between each
immunisation. Rabbits were bled when the antibody titre was
greater than 1:15,000 when tested in an ELISA (Gore et al.,
1984) against CHO- HMFGM. Serum (R2) was prepared
and stored in 100 jIl aliquots at - 30°C.
Characterisation ofantisera to carbohydrates stripped human
milkfat globule membrane
ELISA R2 antisera was tested using an ELISA (Gore et al.,
1984) on HMFGM which was either unstripped of carbo-
hydrate (CHO') or stripped (CHO-). Polystyrene 96-well
microtest plates (Falcon 3912, Becton-Dickinson) were
coated with 5lag of protein per well. Primary antisera (R2)
and secondary antisera (goat anti-rabbit IgG urease con-
jugate, used at 1:120, obtained from CSL, Sera-Lab, Crawley
Down, United Kingdom) were diluted in PBS/2% (w/v)
BSA. After colour development with urease substrate (CSL,
Sera-Lab) the absorbance of the wells was determined at
580 nm.
Immunohistochemistry with R2
Sections from methacarn fixed, paraffin embedded normal
breast, primary breast carcinoma and other normal tissues
were stained with R2 antisera to CHO- HMFGM (diluted to
1:500 in PBS/1% BSA) using an alkaline phosphatase linked
goat anti-rabbit IgG secondary antibody and standard pro-
tocols (Foster et al., 1982).
Immunoblotting
100 lAg of CHO- HMFGM were separated on a 10% PAGE/
SDS gel (Laemmli, 1970) and proteins transferred electro-
phoretically to nitrocellulose (Burnette, 1981). Binding of
primary antibody was detected with a goat anti-rabbit IgG
horseradish peroxidase conjugate (Bio-Rad, Watford, United
Kingdom).
cDNA library construction
Total RNA was extracted (Chirgwin et al., 1979) from a
breast metastatic lymph node and poly A + selected by
standard oligo dT chromatography. cDNA was synthesised
using the S1 nuclease method (Huynh et al., 1985) and
inserted into the expression vector lambda gtl1 using EcoRI
linkers. Following packaging the library of approximately
3 x 105 independent clones (of which 85% contained re-
combinant inserts), was amplified by plating on E. coli Y1088.
Immunoscreening ofcDNA library
The R2 antiserum was preabsorbed with a lysate of E. coli
Y1090 for 2-3 h at 20°C to reduce binding to E. coli
antigens. About I05 phage were screened with R2 using a
Promega Protoblot immunoscreening kit. Positives were
purified to homogeneity by two further rounds of re-
screening.
Amplification and excision ofcDNA inserts
Recombinant inserts were excised, purified and amplified
from single plaques by means of PCR. From the equivalent
of 1/4 of a plaque, 1-2 jLg of insert was obtained using 1 jLm
each of a pair of primers homologous to sequences flanking
the EcoRl insertion site within the lac Z gene of lambda
gtl1, as described by Saiki & colleagues (Saiki et al., 1988).
The PCR products were digested with EcoRl to remove
the short lac Z flanking sequences, and purified by electro-
phoresis on low melting agarose gels containing ethidium
bromide. Bands were excised and after appropriate dilution
(Feinberg & Vogelstein, 1983) with H20 the cDNA was
stored at - 20°C. For subcloning, the cDNA was extracted
from the agarose by the glass powder method using the
Geneclean Kit (Stratagene).
RNA extraction andhybridisation
Total cellular RNA was extracted from frozen tissues using
the guanidinium isothiocyanate procedure (Chirgwin et al.,
1979), and from cultured cells by the modified RNA-Zol
(Biogenesis, UK) method described previously (Luqmani et
al., 1989).
Northern analysis was performed by electrophoresis of
total RNA (20jg per lane) denatured by the glyoxylation
method (Maniatis et al., 1982) and capillary transfer to
Hybond N or N + membranes (Amersham, UK).
Hybridisations were performed using standard protocols
(Bennett et al., 1989); cDNA probes were labelled directly in
low melting agarose using the random primer technique
(Feinberg & Vogelstein, 1983) with 32P-dCTP (Amersham,
UK) to specific activities of 5 x 108-10 c.p.m.jLg-. Autoradiographic signals obtained on Amersham hyperfilm
were scored by comparison to serially diluted standards made
from the PCR products. Blots were checked for even loading
by hybridisation to a reference probe. To simplify analyses,
expression of J16 was recorded only as positive or undetect-
able.
Plaque hybridisation
Screening of lambda plaques transferred to Hybond N mem-
branes with 32P-labelled cDNA was performed using estab-
lished protocols (Benton & Davies, 1977).
DNA sequencing
Geneclean purified cDNA was ligated into M13. Single
str4nded templates were subjected to sequencing by the
dideoxy chain termination procedure (Veira & Messing,
1982) using the Applied Biosystems model 370A DNA
sequencer.
Lactoferrin and ER immunocytochemistry
Lactoferrin staining was performed using a polyclonal
antisera from Dako Ltd (Buckinghamshire, UK), and an
ABS Vectastain kit from Vector Laboratories (Peterborough,
UK) essentially as per manufacturers instructions except that
the paraffin sections were trypsinised for 30 min at 37°C prior
to staining. ER staining was performed on frozen sections as
described previously (Barret-Lee et al., 1987) with the Abbott
monoclonal H222 antibody.
Results
Preparation ofHMFGM antigen and reactivity ofantisera
The Trimethylsulfonyl fluoride treatment reduced the carbo-
hydrate content of the HMFGM by approximately 98%
from the initial content of 248 jig mg-' protein, to
< 5 jigmg-' protein. When injected into rabbits, this
immunogen produced an antisera which at 1:25,000 dilutionLACTOFERRIN IN HUMAN BREAST 21
still retained 27% of its maximal activity against HMFGM
in an ELISA. When tested against CHO-HMFGM we
observed a binding capacity of two orders of magnitude
greater than that seen with the CHO' membranes. On
Western blots R2 showed extensive reactivity with several
discrete bands up to approximately 150 Mr (data not shown).
In an immunohistochemical screen, we observed a strong
reaction to the epithelial component of both normal breast
and primary breast carcinomas. Epithelial cells of skin also
showed strong reactivity as did several other tissues (data not
shown).
Screening ofcDNA library
Approximately IO' pfu from the lambda gtl1 library were
screened with the R2 antiserum. The initial 38 isolates were
reduced to 20 positive clones on subsequent rescreenings.
The cDNA inserts from these were amplified by the PCR
technique and gel purified EcoRl digested cDNA's were used
for cross hybridisation to plaques of the 20 clones. This
process ofelimination yielded eight independent clones whose
PCR products showed approximate sizes of 1350bp (JI),
350bp (J8), 310bp (J16), 650bp (J31) (Figure 1) and 60bp
Figure 1 Amplification of recombinant inserts from the lambda
gtl 1 library. Lanes 1-4: clones JI, J8, J16, J31 respectively.
Molecular size markers (lane M) are Haelll digested phixl74
DNA. Well isolated immunopositive plaques from tertiary
screens of the RSI1 library were excised with a pasteur pipette
and DNA eluted from the agar plugs in 2001il H20 for at least
1 h: 50Al aliquots were subjected to 30 cycles of amplification
using primers flanking the EcoRl insertion site (31). About 1/5th
of the products were electrophoresed on 2% agarose and stained
with ethidium bromide.
(Jll, J14, J28, J35). The four larger clones were taken for
further analysis. Partial sequence data were obtained for
these and using computer assisted homology searches of the
EMBL data banks, we found no significant homologies for
JI and J8. The J31 clone showed identity with human
immunoglobulin kappa light chain variable region (V-J) and
the C terminal region. The 240 bases determined for the J16
clone were entirely homologous to the 3' coding region (posi-
tion 580-819) of the human lactoferrin gene (Rado et al.,
1987; Metz-Boutigue et al., 1984). This was investigated in
more detail.
Expression ofthe J16 clone in breast tissue
In all cases where J16 was expressed, we observed a single
invariant band corresponding to a message size of approxi-
mately 2.5 kb. The greatest levels of J16 mRNA were
detected in lactating breast, but it was also highly expressed
in non-lactating normal breast tissue (Figure 2). Hybridisa-
tion was seen in biopsies, from 15/19 patients, taken from
tissue adjacent to carcinoma. RNA extracted from organoid
preparations from three separate reduction mammoplasties
also has high levels of J16.
To determine whether J16 was expressed in cancer, we
examined 59 primary breast tumours. Forty-four per cent of
these had no detectable message. The other 56% showed
Figure 2 Northern analysis of normal (N) and lactating (L)
breast tissue. Total glyoxylated RNA (20jsg) was electrophoresed
on 1% agarose, blotted onto Hybond membrane and hybridised
to 32P-labelled J16 cDNA. Exposure to Hyperfilm was for 4 days
at - 70C using intensifying screens. The positions of yeast (28S,
18S) and E.coli (23S, 16S) rRNA markers are indicated. The
single band was estimated at 2.5 kb.22 T. CAMPBELL et al.
variable degrees of hybridisation but generally at lower levels
than seen for the normal samples (Figure 3). We examined
various clinical parameters and found no correlation with
patient age, menopausal status, nodal involvement, tumour
grade, pathology or T stage.
ER staining data (Barrett-Lee et al., 1987) was obtained
for 59 tumours: concurrent expression of ER and J16 was
found in 13/36, whereas for ER negative tumours 20/23 were
J16 positive. This was highly significant (Fishers exact test,
P = 0.0001) (Table I). We also examined the relationship
between J16 hybridisation and previously measured transfor-
ming growth factor(TGF) alpha and epidermal growth factor
receptor (EGFR) mRNA levels (Travers et al., 1988). In a
group of 24 tumours we found that 8/16 which were TGF-
alpha positive were also J16 positive whereas only 2/8 of the
TGF alpha negative ones had J16 expressed. Similarly, a
higher proportion (7/13) of EGFR positive tumours express-
ed J16 than did EGFR negative ones (3/10). Due to the small
numbers, statistical significance was not achieved.
Immunocytochemistry with antisera to lactoferrin
Strong immunoreactivity was observed in sections of lact-
ating breast. The glandular epithelia were homogeneously
stained, as well as the ductal secretions (Figure 4a). Stromal
reaction was negligible. A case ofvirginal hyperplasia was, as
expected, negative. Ducts and lobular structures of normal
appearance contained positive cells as did areas of apocrine
metaplasia (Figure 4b, 5). Often very strong membrane stain-
a
b
c
Figure 3 Expression of J16 in breast carcinoma. Total glyoxy-
lated RNA (20tsg) was separated by agarose gel electrophoresis,
transferred to Hybond membrane and hybridised with 32p_
labelled J16 cDNA. Autoradiography was performed using
Hyperfilm at - 70C with intensifying screens; 12 day exposure.
All tracks except seven (organoid from normal breast mammo-
plasty) contained RNA from primary breast tumours. The posi-
tions of the rRNA are indicated.
Table I Relationship betwen J16 hybridisation and expression of
EGFR and TGF alpha mRNA and immunostaining of ER
J16 hybridisation TGF alpha mRNAa EGFR mRNAa ER stainingb
+ - + - + -
+ 8 2 7 6 13 20
8 6 3 7 23 3
Figure 4 Immunoperoxidase staining of formalin fixed sections
showing lactoferrin protein localisation. a, lactating breast, b,
normal acini of a resting breast, c, invasive ductal carcinoma.
Magnification x 100, a, x 200, b-c.
ing was observed in addition to the more diffuse cytoplasmic
reaction. Again ductal secretions were also stained. Overall,
although the reaction was patchy, it was consistent in the
type of cells involved. In sections of breast cancer, there was
considerably heterogeneity. Immunoreactivity was usually
less intense; odd foci of tumour cells showed membrane
associated positivity, particularly when they formed gland
like structures (Figure 4c). Three cases of fibroadenomas
examined were negative, as well as a Phyllodes tumour. In
most instances very little background staining was seen; lym-
phocytic infiltrations were negative and we observed only
occasional inflammatory cells, which were usually positive.
Frequently, lobules exhibiting mild hyperplasia showed
intense staining, as did radial scars (Figure 5).
aData from Barrett Lee et al., 1987. bJ16 hybridisation inversely
correlated with estrogen receptor positivity: Fishers exact test,
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a (Stampfer & Bartley, 1985). We could not detect J16 expres-
sion in any of these lines in 20 .g of total RNA using
conditions of probe specific activity and hybridisation iden-
tical to those for the tissue RNA.
Table II Clinical details of patients with DCIS
Lactoferrin positive Lactoferrin negative
No. of cases 20 21
Mean patient age (years) 54 50
Mean follow-up time (months) 90 49
No. with family history of 2 5
breast cancer
No. of premenopausal cases 10 (50%) 15 (71%)
No. of postmenopausal cases 10 (50%) 6 (29%)
b
Table III Lactoferrin staining in histological subtypes of DCIS
Total no.
tumours No. positive % Positive
In pure form:
cribriform 14 3 21
comedo 2 1 33
solid 3 1 33
micropapillary 11 9 82
Any tumour involving:
cribriform 8 5 63
comedo 3 1 33
solid 4 2 50
micropapillary 5 4 80
a
Figure 5 Immunoperoxidase staining of formalin fixed sections
with lactoferrin positivity in the acini of two lobules and in the
intralobular ducts exhibiting mild epithelial hyperplasia, a, and in
the epithelial lining of some ducts as well as the luminal secretion
in a radical scar, b. The latter also shows a cyst lined by
positively stained metaplastic apocrine cells (AP).
We also examined 45 cases with DCIS, which usually
appeared as a relatively small component within most sec-
tions. In four of these, we observed some infiltrating car-
cinoma whilst the remainder were purely DCIS, and showed
no invasive components in the sections examined: the former
were therefore excluded.
Twenty showed some degree of lactoferrin immunoreac-
tivity. The clinical details of these are given in Table II. The
breakdown of the various histological subtypes is shown in
Table III. Where present in pure form, the greatest frequency
of positivity, and also intensity, was observed in the micro-
papillary variant (9/11) with least in the cribriform DCIS
(3/14) and in 1/3 solid or comedo sub-types. In those
tumours where we found more than one sub-type, 80% of
those containing any micropapillary DCIS were positive. A
higher proportion of both cribriform and solid DCIS were
positive: four out of the five positive cribriform DCIS had
micropapillary DCIS as the other component. Examples of
the staining pattern are illustrated in Figure 6. Following
various surgical treatments, 14/41 (34%) patients developed
recurrent disease up to the time of follow up; six developed
invasive carcinoma and eight recurrent DCIS (Table IV).
There did not appear to be any relationship between lactofer-
rin staining and recurrence.
Breast cell lines
We prepared RNA from a number of commonly used breast
cancer cell lines, MCF7, T47D, ZR75, MDA231; from HBL
100 and an SV40 transformed line HBrSV1.6.1 which display
some 'normal' characteristics; and from 184AI and 184B5
derived from organoid culture of reduction mammoplasties
b
Figure 6 Sections showing focal cytoplasmic immunoperoxidase
reaction with anti-lactoferrin in DCIS, of the small cell
cribriform/micropapillary, a, or mixed solid and comedo, b,
variants. In the latter, the unfilled arrow points to positive
tumour cells in solid DCIS, and the filled arrows show the
necrotic centres and a few surrounding intact cells in a focus of
comedo carcinoma.24 T. CAMPBELL et al.
Table IV Histology and lactoferrin status of primary tumours of patients with recurrent disease in
the DCIS series
(a) DCIS that recurred as DCIS (b) DCIS that recurred as
invasive carcinoma
Time to Time to
Initial Original recurrence Initial Original recurrence
treatment histology (months) treatment histology (months)
Lactoferrin positive
1. Bx Micropapillary 40 1. m Cribriform 82
2. WLE Micropapillary 66 2. Bx Cribriform/solid 25'
3. Bx Micropapillary 46 3. Bx Solid 95
4. Bx Micropapillary/ 36
Cribriform
5. Bx Cribriform 7
Mean 39 Mean 67
Lactoferrin negative
1. WLE, LID Cribriform 6 1. WLE, DXT Cribriform 149
2. WLE Solid 51 2. Bx Cribriform 31
3. Bx Solid/Comedo 9 3. WLE Cribriform 95
Mean 22 Mean 92
Normal tissue screen
In order to determine whether J16 was expressed in tissues
other than breast, we extracted and probed RNA from
several other human tissues, and the result is illustrated in
Figure 7. A high level of hybridisation was seen in the
sample from normal stomach. The band intensity was as
great as any signal observed from a non-lactating breast
specimen. A faint band was discernible in the track contain-
ing RNA from skin; a similar signal was also observed with a
preparation of lymphocytes (data not shown); no J16 mRNA
was detected in placenta, spleen, muscle, lung, kidney, blad-
der, ovary, colon, thyroid or adrenal gland. These Northern
blots were re-hybridised with other commonly expressed
clones also isolated from the library and strongly positive
signals were obtained in all the tracks, confirming that lack
of J16 hybridisation was not due to insufficient RNA in the
tracks: we cannot exclude expression at levels below our
limits of detection in these experiments.
In view of the positivity seen in the normal stomach speci-
men, we screened five gastric cancer cell lines of various
parental lineages and displaying quite different morphological
characteristics (Motoyama & Watanabe, 1983; Motoyama et
al., 1986). No hybridisation was detected in any of these lines
(MKN-1, MKN-28, MKN-45, KATO 111, SCH).
Discussion
We report a detailed description of the expression of lactofer-
rin mRNA and protein in human breast tissues. We have
found that (a), lactoferrin is present in a subset of normal,
malignant and in situ carcinomas and (b), in carcinomas,
lactoferrin mRNA is present predominantly in the ER
negative tissues.
The J16 clone is homologous to the 3' terminus of the
lactoferrin sequence, which encodes a single glycosylated
polypeptide of -70-80,000 Mr (Teng et al., 1986) which like
transferrin has iron binding properties, and has been found
in human (Sanchez-Pozo et al., 1986; Hegnhj et al., 1986)
exocrine secretions, and has been isolated from milk and
neutrophilic leucocytes (Moguilevsky et al., 1985). A mouse
cDNA clone was isolated form a uterine lambda gtl1 library
by immunoscreening and was found to have -70% homology
with the human sequence (Metz-Boutigue et al., 1984)
recently cloned from a myeloid library using an
oligonucleotide (Rado et al., 1987). The latter authors found
that its expression coincided with granulocytic differentiation.
The distribution of lactoferrin, studied mainly by
immunological methods appears to vary considerably
between species (Teng et al., 1989; Masson & Heremans,
1966; Roberts & Boursnell, 1975) with conflicting data that
presumably reflects both experimental sensitivity (Pentecoste
et al., 1987; Teng et al., 1989) and hormonal status of certain
tissues. A 300-fold induction with oestrogen was observed in
mouse uterus with virtually undetectable amounts in the rat
organ (Pentecoste et al., 1987). Mouse mammary lactoferrin
is reported to be unaffected by circulating oestrogen (Teng et
al., 1989) but is inducible by prolactin using explants from
mid-pregnant mice (Green & Pastewka, 1978).
Our results have shown that lactoferrin, highly expressed
during lactation, is also synthesised by non-lactating breast,
primarily by the ductal cells, these being the predominant
components of organoids with little stromal contribution.
This was confirmed by our immunocytochemical data:
Immunoreactivity was associated with actively secreting cells
in both lactating and resting ducts. To our knowledge this is
Figure 7 Northern blot of RNA extracted from different human
tissues; tracks 1-12 contain 20 tg of glyoxal denatured RNA
from placenta, spleen, muscle, lung, kidney, bladder, ovary,
colon, stomach, adrenal gland, thyroid and skin respectively.
Track 13 shows the positions of the rRNA markers. Electro-
phoresis, blotting and hybridisation with 32P-labelled J16 cDNA
was performed as described under Methods. Autoradiographic
exposure was for 5 days.LACTOFERRIN IN HUMAN BREAST 25
the first systematic study of lactoferrin mRNA expression in
malignancy. Although patchy, foci of tumour cells were
clearly positive, confirming that RNA hybridisation observed
in tumour biopsies was not due exclusively to contaminating
normal elements. No obvious clinical correlate was found
and more tumours are being examined before meaningful
statistical analysis can be performed. The frequency of
positivity reported here is in line with the immuno-
cytochemical data of Wurster et al. (1980) and Wrba et al.
(1986) and it is clear that lactoferrin cannot be considered as
a marker of benign lesions as suggested by Rossiello et al.
(1984). Of the five positive cases reported by Charpin et al.
(1985), two were DCIS. We found lactoferrin in similar
proportions of both invasive and DCIS tumours.
J16 hybridisation tended to be more associated with
invasive tumours lacking ER. Expression was also more
prevalent in tumours which were TGFalpha positive and to a
lesser extent in those that were EGFR positive, compared to
those which were negative for either factor. An inverse cor-
relation between ER and EGFR has been commonly observed
(Sainsbury et al., 1987; Travers et al., 1988) and we have also
shown that TGFalpha transcripts are more expressed in ER
negative cancers and that there is a significant coexpression
of TGFalpha and EGFR which is also more prevalent in the
ER negative tumours (Travers et al., 1988).
ER status is sometimes used to select patients for endo-
crine therapy. The presence of lactoferrin mRNA may be an
additional confirmatory factor in choosing to provide alter-
native treatment for ER negative patients. The tissue screen
showed a selective distribution with high expression only in
normal stomach in agreement with Mason and Taylor (1978).
Again, it is interesting that no expression was seen in the
gastric cell lines; we are currently examining a series of
stomach carcinomas. The lack of expression in spleen, lung,
kidney and ovary is in contrast to the findings in the corre-
sponding mouse tissues by Western blotting (Tend et al.,
1989); a similar discordance exists with duodenum between
mouse and human tissue (Teng et al., 1989; Mason & Taylor,
1978). For kidney and ovary there was some doubt as to the
authenticity of the 65 Mr band (Tend et al., 1989) in these
studies, compared to the 70 Mr protein described earlier
(Teng et al., 1986). It remains to be seen whether these
reported differences reflect true species variability.
Few human tissues (haematopoietic cells aside) are convinc-
ingly positive, with reports of lactoferrin in secretory phase
endometrium (Tourville et al., 1970) and in seminal plasma
(Goodman & Young, 1981) as a major sperm-coating antigen
(Heckman & Rumke, 1969). Immunocytochemical staining
has been reported (Mason & Taylor, 1978) in gastric mucus
neck cells, some duodenal absorptive epithelia, glandular
bronchial glands and most strongly in glandular epithelia
(and their secretions) of lactating breast; also in the odd
sample of uterus and a basal cell skin carcinoma. An exten-
sive study (Hulseweische et al., 1989) of gastric tumours
showed lactoferrin expression in biopsies associated with
inflammation, but its absence was noted from mucoepider-
moid carcinomas (Kumasa et al., 1988).
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